XOMA FINANCIAL STATEMENTS

XOMA Royalty Corporation — balance sheet, income statement and cash flow trends

XOMAXOMA Royalty Corporation

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue36.2 M $-3.3%

Gross Profit33.8 M $-4.1%

Operating Income5 M $—

EBITDA50.2 M $—

Net Income31.5 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
XOMA	-3.3%	93.3%	138.4%	87.0%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
XOMA	-3.3%	93.3%	138.4%	87.0%
RIGL	47.6%	93.4%	43.8%	121.5%
ACRS	-52.9%	76.3%	-843.9%	-832.6%
RGNX	-44.0%	-0.1%	-261.2%	-330.2%
CRMD	384.6%	85.8%	53.2%	45.2%
PRME	-90.3%	-1,082.7%	-4,732.2%	-4,917.6%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity112.9 M $42%
Current Liabilities33.1 M $12%
Long-term Liabilities125.9 M $46%

Key Figures

YoY change

Total Assets271.9 M $+27.8%

Total Liabilities159 M $+24.1%

Total Equity112.9 M $+33.4%

Cash & ST Investments95 M $+2.5%

Total Debt124.7 M $+9.0%

Net Debt30.3 M $+25.1%

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
XOMA	3.59	110.5%	0.59	41.5%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
XOMA	3.59	110.5%	0.59	41.5%
RIGL	2.62	11.4%	-0.77	79.2%
ACRS	4.03	1.4%	1.46	72.3%
RGNX	2.62	337.1%	0.35	6.2%
CRMD	2.98	33.2%	-0.16	53.6%
PRME	3.80	149.3%	0.11	26.0%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow6.6 M $—

Capital Expenditures111 K $+3,600.0%

Free Cash Flow6.6 M $—

Dividends Paid-5.5 M $-201.0%

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
XOMA	18.3%	18.3%	0.3%	21.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
XOMA	18.3%	18.3%	0.3%	21.1%
RIGL	26.4%	26.4%	0.0%	21.8%
ACRS	-623.9%	-624.8%	1.0%	74.9%
RGNX	-266.2%	-269.2%	3.0%	80.6%
CRMD	49.4%	49.1%	0.3%	109.2%
PRME	-3,877.5%	-3,935.1%	57.6%	78.8%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on XOMA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.